Precision BioSciences, Inc.
NASDAQ:DTILBiotechnology
+$0.11 today
- Market cap
- $198.34M
- Beta
- 1.28
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$3.47
Volume 0.37M
Average 0.31M
DTIL Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Precision BioSciences, Inc.NASDAQ: DTIL
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How DTIL compares with its peers on the latest reported figures
- DTIL's Mar 2026 Accumulated OCI of $0 is the 2nd highest of the 7 companies compared; the peer median is -$3K.
- Accumulated OCI amounts to 0.0% of total assets for DTIL, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $21K | +40.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$6K | -700.0% | — | 0.0% | |
| Mar 2026 | -$104K | -154.5% | — | 0.0% | |
| Mar 2026 | -$4.02M | -388.3% | — | 3.1% | |
| Peer median (excluding DTIL) | -$3K | -271.4% | — | 0.0% | |
Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 143.66M | 189.58M | 116.68M | 85.9M | 110.82M |
| Short-term Investments | 0 | 0 | 0 | 413K | 4.76M |
| Net Receivables | 488K | 720K | 12.8M | 1.7M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 169K | 2.78M | 906K | 538K | 45K |
| Total Current Assets | 161.75M | 199.11M | 136.36M | 94.99M | 118.74M |
| Property, Plant & Equipment (Net) | 29.33M | 13.78M | 14.6M | 10.18M | 7.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.05M | 731K | 400K | 622K | 1.17M |
| Long-term Investments | 6.84M | 4.75M | 3.21M | 3.21M | 744K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 11.52M | 19.81M | 5.22M | 27.39M | 26.54M |
| Total Non-current Assets | 49.74M | 39.06M | 23.42M | 41.4M | 35.68M |
| Total Assets | 211.5M | 238.17M | 159.78M | 136.39M | 154.42M |
| Account Payables | 1.14M | 653K | 2.97M | 1.31M | 296K |
| Short-term Debt | 0 | 0 | 22.41M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 21.24M | 46.19M | 12.04M | 2.96M | 0 |
| Other Current Liabilities | 7.74M | 9.31M | 9.88M | 7.38M | 2.36M |
| Total Current Liabilities | 35.98M | 59.66M | 49.99M | 14.98M | 8.91M |
| Long-term Debt | 2.48M | 22.22M | 0 | 22.32M | 22.4M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 77.02M | 92.87M | 83.08M | 33.3M | 10M |
| Other Non-current Liabilities | 44K | 1.92M | 128K | 2.99M | 15.95M |
| Total Non-current Liabilities | 84.35M | 118.07M | 90.93M | 65.02M | 53.26M |
| Total Liabilities | 120.33M | 177.74M | 140.92M | 80M | 62.17M |
| Common Stock | 0 | 1K | 1K | 1K | 1K |
| Retained Earnings | (316.68M) | (428.31M) | (489.63M) | (482.46M) | (528.19M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 91.17M | 60.43M | 18.86M | 56.39M | 92.25M |
| Total Debt | 9.11M | 24.96M | 31.27M | 30.05M | 28.81M |
| Net Debt | (134.55M) | (164.62M) | (85.41M) | (55.85M) | (82.02M) |
Precision BioSciences, Inc.
NASDAQ:DTIL
Intrinsic Alpha fair value
Locked
Current Price
$7.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.